The high price of anticancer drugs

origins, implications, barriers, solutions

Vinay Prasad, Kevin De Jesús, Sham Mailankody

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Globally, annual spending on anticancer drugs is around US$100 billion, and is predicted to rise to $150 billion by 2020. In the USA, a novel anticancer drug routinely costs more than $100,000 per year of treatment. When adjusted for per capita spending power, however, drugs are most unaffordable in economically developing nations, such as India and China. Not only are launch prices high and rising, but individual drug prices are often escalated during exclusivity periods. High drug prices harm patients — often directly through increased out-of-pocket expenses, which reduce levels of patient compliance and lead to unfavourable outcomes — and harms society — by imposing cumulative price burdens that are unsustainable. Moreover, high drug prices are not readily explained by rational factors, including the extent of benefit patients are likely to derive, the novelty of the agents, or spending on research and development. Herein, we summarize the available empirical evidence on the costs of anticancer drugs, probe the origins and implications of these high costs, and discuss proposed solutions.

Original languageEnglish (US)
JournalNature Reviews Clinical Oncology
DOIs
StateAccepted/In press - Mar 14 2017

Fingerprint

Drug Costs
Pharmaceutical Preparations
Patient Harm
Patient Compliance
Health Expenditures
Developing Countries
India
China
Costs and Cost Analysis
Research
Therapeutics
Power (Psychology)

ASJC Scopus subject areas

  • Oncology

Cite this

The high price of anticancer drugs : origins, implications, barriers, solutions. / Prasad, Vinay; Jesús, Kevin De; Mailankody, Sham.

In: Nature Reviews Clinical Oncology, 14.03.2017.

Research output: Contribution to journalArticle

@article{9e8b3be1decf4636824d021a3b8aefc9,
title = "The high price of anticancer drugs: origins, implications, barriers, solutions",
abstract = "Globally, annual spending on anticancer drugs is around US$100 billion, and is predicted to rise to $150 billion by 2020. In the USA, a novel anticancer drug routinely costs more than $100,000 per year of treatment. When adjusted for per capita spending power, however, drugs are most unaffordable in economically developing nations, such as India and China. Not only are launch prices high and rising, but individual drug prices are often escalated during exclusivity periods. High drug prices harm patients — often directly through increased out-of-pocket expenses, which reduce levels of patient compliance and lead to unfavourable outcomes — and harms society — by imposing cumulative price burdens that are unsustainable. Moreover, high drug prices are not readily explained by rational factors, including the extent of benefit patients are likely to derive, the novelty of the agents, or spending on research and development. Herein, we summarize the available empirical evidence on the costs of anticancer drugs, probe the origins and implications of these high costs, and discuss proposed solutions.",
author = "Vinay Prasad and Jes{\'u}s, {Kevin De} and Sham Mailankody",
year = "2017",
month = "3",
day = "14",
doi = "10.1038/nrclinonc.2017.31",
language = "English (US)",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - The high price of anticancer drugs

T2 - origins, implications, barriers, solutions

AU - Prasad, Vinay

AU - Jesús, Kevin De

AU - Mailankody, Sham

PY - 2017/3/14

Y1 - 2017/3/14

N2 - Globally, annual spending on anticancer drugs is around US$100 billion, and is predicted to rise to $150 billion by 2020. In the USA, a novel anticancer drug routinely costs more than $100,000 per year of treatment. When adjusted for per capita spending power, however, drugs are most unaffordable in economically developing nations, such as India and China. Not only are launch prices high and rising, but individual drug prices are often escalated during exclusivity periods. High drug prices harm patients — often directly through increased out-of-pocket expenses, which reduce levels of patient compliance and lead to unfavourable outcomes — and harms society — by imposing cumulative price burdens that are unsustainable. Moreover, high drug prices are not readily explained by rational factors, including the extent of benefit patients are likely to derive, the novelty of the agents, or spending on research and development. Herein, we summarize the available empirical evidence on the costs of anticancer drugs, probe the origins and implications of these high costs, and discuss proposed solutions.

AB - Globally, annual spending on anticancer drugs is around US$100 billion, and is predicted to rise to $150 billion by 2020. In the USA, a novel anticancer drug routinely costs more than $100,000 per year of treatment. When adjusted for per capita spending power, however, drugs are most unaffordable in economically developing nations, such as India and China. Not only are launch prices high and rising, but individual drug prices are often escalated during exclusivity periods. High drug prices harm patients — often directly through increased out-of-pocket expenses, which reduce levels of patient compliance and lead to unfavourable outcomes — and harms society — by imposing cumulative price burdens that are unsustainable. Moreover, high drug prices are not readily explained by rational factors, including the extent of benefit patients are likely to derive, the novelty of the agents, or spending on research and development. Herein, we summarize the available empirical evidence on the costs of anticancer drugs, probe the origins and implications of these high costs, and discuss proposed solutions.

UR - http://www.scopus.com/inward/record.url?scp=85015240708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015240708&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2017.31

DO - 10.1038/nrclinonc.2017.31

M3 - Article

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

ER -